Galectin Therapeutics (GALT) Amortization of Deferred Charges (2020 - 2024)
Galectin Therapeutics' (GALT) quarterly Amortization of Deferred Charges came in at $10000.0 in Q4 2024, up 11.11% year-on-year from $9000.0 in Q1 2024, and up 11.11% quarter-over-quarter from $9000.0 in Q3 2024.
Galectin Therapeutics (GALT) Amortization of Deferred Charges (2020 - 2024) Analysis & Trends
Galectin Therapeutics' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $10000.0 for Q4 2024.
- On a quarterly basis, Amortization of Deferred Charges rose 11.11% year-over-year to $10000.0 in Q4 2024; TTM through Dec 2024 was $37000.0, a 12.12% increase from a year earlier, with the FY2025 full-year figure at $53000.0, up 43.24% from the prior year.
- Amortization of Deferred Charges grew to $10000.0 in Q4 2024 per GALT's latest filing, from $9000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $32000.0 in Q1 2023 and bottomed at -$16000.0 in Q2 2023.
- The 5-year median for Amortization of Deferred Charges is $9000.0 (2020), against an average of $8941.2.
- Biggest YoY gain for Amortization of Deferred Charges was 220.0% in 2023; the steepest drop was 328.57% in 2023.
- Year by year, Amortization of Deferred Charges stood at $9000.0 in 2020, then grew by 22.22% to $11000.0 in 2021, then slipped by 27.27% to $8000.0 in 2022, then rose by 12.5% to $9000.0 in 2023, then gained by 11.11% to $10000.0 in 2024.
- Per Business Quant, the three latest GALT Amortization of Deferred Charges figures stand at $10000.0 (Q4 2024), $9000.0 (Q3 2024), and $9000.0 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 227.69 Mn | 227.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Sep 30, 2022 | 7,000.00 |